Logo image of XNCR

XENCOR INC (XNCR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XNCR - US98401F1057 - Common Stock

15.87 USD
+0.29 (+1.89%)
Last: 11/21/2025, 8:06:20 PM
15.87 USD
0 (0%)
After Hours: 11/21/2025, 8:06:20 PM
Fundamental Rating

3

Overall XNCR gets a fundamental rating of 3 out of 10. We evaluated XNCR against 535 industry peers in the Biotechnology industry. While XNCR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, XNCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XNCR has reported negative net income.
In the past year XNCR has reported a negative cash flow from operations.
In the past 5 years XNCR reported 4 times negative net income.
XNCR had negative operating cash flow in 4 of the past 5 years.
XNCR Yearly Net Income VS EBIT VS OCF VS FCFXNCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

With a decent Return On Assets value of -15.97%, XNCR is doing good in the industry, outperforming 80.00% of the companies in the same industry.
The Return On Equity of XNCR (-22.19%) is better than 82.99% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -22.19%
ROIC N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
XNCR Yearly ROA, ROE, ROICXNCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

XNCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XNCR Yearly Profit, Operating, Gross MarginsXNCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

5

2. Health

2.1 Basic Checks

XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XNCR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XNCR has been increased compared to 5 years ago.
The debt/assets ratio for XNCR has been reduced compared to a year ago.
XNCR Yearly Shares OutstandingXNCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XNCR Yearly Total Debt VS Total AssetsXNCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 1.85 indicates that XNCR is not a great score, but indicates only limited risk for bankruptcy at the moment.
XNCR's Altman-Z score of 1.85 is fine compared to the rest of the industry. XNCR outperforms 66.73% of its industry peers.
XNCR has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of XNCR (0.14) is worse than 64.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 1.85
ROIC/WACCN/A
WACC8.4%
XNCR Yearly LT Debt VS Equity VS FCFXNCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

XNCR has a Current Ratio of 5.99. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR has a better Current ratio (5.99) than 63.18% of its industry peers.
XNCR has a Quick Ratio of 5.99. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR's Quick ratio of 5.99 is fine compared to the rest of the industry. XNCR outperforms 64.67% of its industry peers.
Industry RankSector Rank
Current Ratio 5.99
Quick Ratio 5.99
XNCR Yearly Current Assets VS Current LiabilitesXNCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

XNCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.69%, which is quite impressive.
The Revenue has grown by 96.51% in the past year. This is a very strong growth!
Measured over the past years, XNCR shows a decrease in Revenue. The Revenue has been decreasing by -6.75% on average per year.
EPS 1Y (TTM)44.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.73%
Revenue 1Y (TTM)96.51%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%96.07%

3.2 Future

The Earnings Per Share is expected to grow by 10.42% on average over the next years. This is quite good.
The Revenue is expected to grow by 39.44% on average over the next years. This is a very strong growth
EPS Next Y26.65%
EPS Next 2Y7.02%
EPS Next 3Y7.32%
EPS Next 5Y10.42%
Revenue Next Year119.19%
Revenue Next 2Y40.25%
Revenue Next 3Y32.66%
Revenue Next 5Y39.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XNCR Yearly Revenue VS EstimatesXNCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
XNCR Yearly EPS VS EstimatesXNCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XNCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XNCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XNCR Price Earnings VS Forward Price EarningsXNCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XNCR Per share dataXNCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.02%
EPS Next 3Y7.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XNCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENCOR INC

NASDAQ:XNCR (11/21/2025, 8:06:20 PM)

After market: 15.87 0 (0%)

15.87

+0.29 (+1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners114.72%
Inst Owner Change-4.77%
Ins Owners1.1%
Ins Owner Change0.98%
Market Cap1.13B
Revenue(TTM)167.36M
Net Income(TTM)-138.75M
Analysts84.21
Price Target28.47 (79.4%)
Short Float %12.43%
Short Ratio6.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.4%
Min EPS beat(2)44.19%
Max EPS beat(2)88.61%
EPS beat(4)3
Avg EPS beat(4)36.93%
Min EPS beat(4)-7.54%
Max EPS beat(4)88.61%
EPS beat(8)4
Avg EPS beat(8)-15.47%
EPS beat(12)7
Avg EPS beat(12)0.09%
EPS beat(16)10
Avg EPS beat(16)90.88%
Revenue beat(2)1
Avg Revenue beat(2)37.58%
Min Revenue beat(2)-24.18%
Max Revenue beat(2)99.34%
Revenue beat(4)3
Avg Revenue beat(4)74.2%
Min Revenue beat(4)-24.18%
Max Revenue beat(4)165.74%
Revenue beat(8)3
Avg Revenue beat(8)22.23%
Revenue beat(12)6
Avg Revenue beat(12)26.44%
Revenue beat(16)9
Avg Revenue beat(16)40.88%
PT rev (1m)13.66%
PT rev (3m)8.27%
EPS NQ rev (1m)15.81%
EPS NQ rev (3m)14.66%
EPS NY rev (1m)1.37%
EPS NY rev (3m)3.63%
Revenue NQ rev (1m)5.13%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.76
P/FCF N/A
P/OCF N/A
P/B 1.81
P/tB 1.84
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS2.35
BVpS8.77
TBVpS8.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -22.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.94%
Cap/Sales 2.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.99
Quick Ratio 5.99
Altman-Z 1.85
F-Score3
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)252.19%
Cap/Depr(5y)241.55%
Cap/Sales(3y)15.72%
Cap/Sales(5y)12.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.73%
EPS Next Y26.65%
EPS Next 2Y7.02%
EPS Next 3Y7.32%
EPS Next 5Y10.42%
Revenue 1Y (TTM)96.51%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%96.07%
Revenue Next Year119.19%
Revenue Next 2Y40.25%
Revenue Next 3Y32.66%
Revenue Next 5Y39.44%
EBIT growth 1Y44.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.83%
EBIT Next 3Y11.28%
EBIT Next 5Y9.12%
FCF growth 1Y4.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.34%
OCF growth 3YN/A
OCF growth 5YN/A

XENCOR INC / XNCR FAQ

Can you provide the ChartMill fundamental rating for XENCOR INC?

ChartMill assigns a fundamental rating of 3 / 10 to XNCR.


What is the valuation status for XNCR stock?

ChartMill assigns a valuation rating of 0 / 10 to XENCOR INC (XNCR). This can be considered as Overvalued.


Can you provide the profitability details for XENCOR INC?

XENCOR INC (XNCR) has a profitability rating of 2 / 10.